Unknown

Dataset Information

0

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.


ABSTRACT:

Background

IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4.

Methods

MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeated single doses were administered the day after chemotherapy at D2 and D16 of the 28-day cycles of paclitaxel (80 mg/m2 at D1, D8 and D15, for 6 cycles). Blood samples were taken 13 days after the sixth and the twelfth IMP321 injections to determine sustained APC, NK and memory CD8 T cell responses.

Results

Thirty MBC patients received IMP321 in three cohorts (doses: 0.25, 1.25 and 6.25 mg). IMP321 induced both a sustained increase in the number and activation of APC (monocytes and dendritic cells) and an increase in the percentage of NK and long-lived cytotoxic effector-memory CD8 T cells. Clinical benefit was observed for 90% of patients with only 3 progressors at 6 months. Also, the objective tumor response rate of 50% compared favorably to the 25% rate reported in the historical control group.

Conclusions

The absence of toxicity and the demonstration of activity strongly support the future development of this agent for clinical use in combined first-line regimens.

Trial registration

ClinicalTrials.gov NCT00349934.

SUBMITTER: Brignone C 

PROVIDER: S-EPMC2920252 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.

Brignone Chrystelle C   Gutierrez Maya M   Mefti Fawzia F   Brain Etienne E   Jarcau Rosana R   Cvitkovic Frédérique F   Bousetta Nabil N   Medioni Jacques J   Gligorov Joseph J   Grygar Caroline C   Marcu Manon M   Triebel Frédéric F  

Journal of translational medicine 20100723


<h4>Background</h4>IMP321 is a recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation. We report clinical and biological results of a phase I/II in patients with metastatic breast carcinoma (MBC) receiving first-line paclitaxel weekly, 3 weeks out of 4.<h4>Methods</h4>MBC patients were administered one dose of IMP321 s.c. every two weeks for a total of 24 weeks (12 injections). The repeat  ...[more]

Similar Datasets

| S-EPMC6964136 | biostudies-literature
| S-EPMC7283477 | biostudies-literature
| S-EPMC8810621 | biostudies-literature
| S-EPMC4606554 | biostudies-literature
| S-EPMC5902232 | biostudies-literature
| S-EPMC9178436 | biostudies-literature
| S-EPMC9724069 | biostudies-literature
| S-EPMC5955142 | biostudies-other
| S-EPMC3488474 | biostudies-other
| S-EPMC3979135 | biostudies-literature